Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc., a leading biotechnology company headquartered in the United States, has been at the forefront of innovative drug delivery solutions since its founding in 1998. Specialising in the development of enzyme-based therapies, Halozyme focuses on enhancing the efficacy of biologic drugs through its proprietary Hylenex® recombinant technology, which facilitates the subcutaneous delivery of therapeutics. With a strong presence in the biopharmaceutical industry, Halozyme has established strategic partnerships with major pharmaceutical companies, significantly expanding its market reach. Notable achievements include the successful integration of its technology into various therapeutic areas, including oncology and diabetes care. As a pioneer in the field, Halozyme continues to drive advancements in drug delivery, positioning itself as a key player in the evolving landscape of biotechnology.
DitchCarbon Score
How does Halozyme Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Halozyme Therapeutics, Inc.'s score of 18 is higher than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Halozyme Therapeutics, Inc.'s reported carbon emissions
In 2023, Halozyme Therapeutics, Inc., headquartered in the US, reported total carbon emissions of approximately 2,318,717 kg CO2e. This figure includes about 1,460,784 kg CO2e from Scope 1 emissions, which encompass direct emissions from owned or controlled sources, and approximately 862,933 kg CO2e from Scope 2 emissions, representing indirect emissions from the generation of purchased electricity, steam, heating, and cooling. As of the latest data, Halozyme has not disclosed any specific reduction targets or initiatives aimed at decreasing their carbon footprint. The absence of defined climate commitments suggests that the company may still be in the early stages of developing a comprehensive sustainability strategy. In the context of the biotechnology industry, where climate impact is increasingly scrutinised, Halozyme's emissions data highlights the importance of establishing clear climate goals and reduction strategies to align with global sustainability efforts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | |
|---|---|
| Scope 1 | 1,460,784.25 |
| Scope 2 | 862,932.72 |
| Scope 3 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Halozyme Therapeutics, Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
